Bernhard Mohr
Managing Director @ Evonik Venture Capital
Frankfurt, Germany
Bernhard Mohr is a venture - series unknown investor at Evonik Venture Capital in Frankfurt focused on 3D Printing and Health Care. Bernhard Mohr has headed the team founding Evonik Corporate Venturing. Prior to joining Evonik, Bernhard was a member of the BASF Venture Capital Team from 2006 until 2011. He has held senior positions in the BASF Group since 1996 and has an international expertise in marketing, finance, corporate development and research & development.Bernhard studied chemistry at the Universities of Stuttgart, Germany and Cincinnati, USA and earned a doctorate from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He held postdoctoral appointments in Japan, France and USA.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Bernhard Mohr invests in
Stages Bernhard Mohr invests in
Countries Bernhard Mohr invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- 3D Printing 4 (22%)
- Health Care 3 (17%)
- Biotechnology 3 (17%)
- Manufacturing 3 (17%)
- Medical 2 (11%)
Stage
- Venture - Series Unknown 6 (33%)
- Series A 3 (17%)
- Series D 2 (11%)
- Seed 1 (6%)
- Series B 1 (6%)
Country
- China 3 (17%)
- United States 3 (17%)
- The Netherlands 2 (11%)
- France 1 (6%)
- Israel 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Abolis is a French company delivering high-impact innovations in biotechnologies that supports industries in their transition to build a better future in collaboration with Nature. We provide tailor-made industrial solutions based on micro-organisms. Founded in 2014, Abolis is made up of a team of over 54 people, sharing a scientific and humanistambition. Determined to become a key player in the transformation of manufacturing, we combine our expertise in biology, fermentation, IT, robotics, analytics and industrial property to reinvent the future of numerous industries - from food to healthcare, cosmetics and chemicals. We help industries make the ecological transition by rethinking their production models We rely on biotechnologies and the untapped potential of micro-organisms to develop new bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. We take up the industry's current challenges by: · Using renewable raw materials · Relocate essential production and secure supply chains · Designing biocompatible products less toxic for the environment · Reducing greenhouse gas emissions Abolis is providing tailor-made industrial solutions, based on microorganisms We are… independent in thought and action rigorous in our approach and the way we work creative because we never stop innovating, while remaining pragmatic ambitious because we are passionate and determined to make a difference | $38.8M / Venture - Series Unknown / Sep 12, 2024 | ||
| Strohm is a private supply chain company, focused on the offshore wind-to-hydrogen sector. | $31.8M / Venture - Series Unknown / Jun 19, 2024 | ||
| HPNow is pioneering the market introduction of powerful, autonomous, safe and eco-friendly water and air treatment solutions, based on their technological breakthroughs in on-site generation of hydrogen peroxide. HPNow’s technology enables on-demand, highly-efficient production of hydrogen peroxide using only water, electricity and air.Withtheir compact and autonomous on-site HPGenTM hydrogen-peroxide generators, they are set to displace presently used and increasingly regulated chlorine and other toxic-chemical disinfectants across multiple water and air treatment sectors. In doing so they will provide our users with cost savings, reduced logistical burdens, and increased yields, while enhancing water, air and food safety and reducing the environmental impact of today’s toxic disinfectant agents. | $15M / Series A / Sep 19, 2023 | ||
| SuperC is an enterprise that specializes in the research and production of innovative nanomaterials. The company was founded in 2012 and is headquartered in Dongguan City, Guangdong, China. | Venture - Series Unknown / Feb 20, 2023 | ||
| Kuva Systems has developed an industrial IoT solution that continuously monitors and quantifies the intensity of methane and VOC emissions. Our infrared imaging system automatically detects and measures emissions and provides operators with an annotated video clip of the leak.Kuva Systems was founded in 2015 and headquartered in Cambridge,Massachusetts. | $11.3M / Series A / Jan 25, 2023 | ||
| Strohm is a private supply chain company, focused on the offshore wind-to-hydrogen sector. | $16M / Venture - Series Unknown / Dec 15, 2022 | ||
| Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | Series C / Dec 13, 2022 | ||
| Strohm is a private supply chain company, focused on the offshore wind-to-hydrogen sector. | $14.4M / Venture - Series Unknown / Aug 12, 2022 | ||
| Union-tek start to engage in the 3D printing technology applicalion. | $31.4M / Series D / Dec 21, 2021 | ||
| UnionTech 3D is active in the field of stereolithography 3D printing. This additive manufacturing technology makes it possible, to produce highly accurate and detailed polymer parts. | $30M / Series D / Dec 21, 2021 | ||
| See all 18 investments → | |||
Co-Investors
About Evonik Venture Capital
Evonik Venture Capital is the corporate venture arm of Evonik Industries AG, one of the providers of specialty chemicals. Evonik Venture Capital invests in young companies with innovative technology and high growth potential with solutions to problems within the areas of focus of resource efficiency, specialty additives, health & care,nutrition.
Evonik Venture Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bernhard Mohr
Managing Director
|
|||
Eric Breese
Investment Director
|
|||
Lars Bönisch
Venture Capitalist
|
|||
|
Thomas Grosse-Puppendahl
Vice President, Operations
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bernhard Mohr invest in?
Bernhard Mohr invests primarily in 3D Printing, Health Care and Biotechnology startups, most often at Venture - Series Unknown and Series A stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bernhard Mohr?
Public channels for Bernhard Mohr include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bernhard Mohr last invest?
The most recent investment recorded for Bernhard Mohr closed in Sep 2024. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
